-

RefleXion Launches Pivotal Study to Expand SCINTIX Therapy and Announces Broader Medicare Reimbursement

Hackensack Meridian John Theurer Cancer Center initiates new clinical study

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion® Medical, an external-beam theranostic oncology company, today announced initiation of the BIOGUIDE-X2 clinical study to expand indications for SCINTIX® biology-guided radiotherapy at Hackensack Meridian John Theurer Cancer Center, a research partner with Georgetown’s Lombardi Comprehensive Cancer Center, an NCI-designated comprehensive cancer center.

“We are buoyed by the initiation of the BIOGUIDE-X2 clinical study, designed as a multi-cohort study for patients with cancers in the liver and abdomen as the first cohorts," Sean Shirvani, M.D., M.P.H.

Share

The company also announced key updates from the Centers for Medicare and Medicaid (CMS) Services. Starting in 2025, CMS will provide broader reimbursement for SCINTIX therapy, including new codes for freestanding cancer centers (FSC) and professional reimbursement for physicians in FSC and hospital outpatient departments.

“The achievement of these milestones sets the stage for substantial expansion in both the indications for and access to SCINTIX therapy," said Sean Shirvani, M.D., M.P.H., chief medical officer at RefleXion. "Given that 40% of American cancer patients receive radiation therapy in freestanding centers1, securing reimbursement for these facilities was imperative, as it eliminates payment barriers for providers adopting new technologies and grants patients access to innovative treatment options.”

The Medicare updates simplify and expand reimbursement, allowing approximately 400,000 additional patients,2 including those suffering from metastatic disease, access to SCINTIX therapy. These changes also support physicians by introducing a professional payment coding mechanism, acknowledging the increased effort necessary to facilitate the widespread adoption of this groundbreaking technology.

“We are also buoyed by the initiation of the BIOGUIDE-X2 clinical study, designed as a multi-cohort study for patients with cancers in the liver and abdomen as the first cohorts. We are grateful to our clinical champions at all our sites for their assistance in designing and implementing this study,” continued Shirvani.

The BIOGUIDE-X2 study is intended to expand SCINTIX therapy from current lung and bone indications to include patients with liver, gallbladder, pancreatic, pelvic, head-and-neck, and other solid tumor cancers. The multi-site, multi-cohort study will gather data at six clinical sites, including Hackensack Meridian John Theurer Cancer Center in New Jersey, over the next several months.

About RefleXion Medical

RefleXion Medical, headquartered in Hayward, Calif., develops and commercializes SCINTIX biology-guided radiotherapy, a groundbreaking treatment that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to single or multiple tumors. SCINTIX therapy is indicated for use in FDG-guided treatment of lung and bone tumors and is being studied for broader indications. In addition, the company offers the RefleXion® X1 system for conventional radiotherapy for all solid tumors located anywhere in the body. More information may be found at https://reflexion.com/.

__________________________
1
https://docs.house.gov/meetings/IF/IF14/20171108/106599/HHRG-115-IF14-Wstate-KavanaghB-20171108.pdf
2 Ibid

Contacts

Media Contact:
Amy Cook
acook@reflexion.com
Media Resources

RefleXion Medical

Details
Headquarters: Hayward, CA
CEO: Todd Powell
Employees: 265
Organization: PRI

Release Versions

Contacts

Media Contact:
Amy Cook
acook@reflexion.com
Media Resources

Social Media Profiles
More News From RefleXion Medical

RefleXion Announces Executive Appointments

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the appointment of Steve Schoch as chief financial officer (CFO) and the promotion of Phil Aulson to chief operating officer (COO). Both report to Todd Powell, RefleXion’s president and chief executive officer. “Steve’s 30-year track record of excellence and diverse background will be a tremendous asset to the RefleXion team,” said Powell. “He brings extensive experience in fundraising, financia...

RefleXion Expands Access to SCINTIX Therapy with First Freestanding Cancer Center

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a theranostic oncology company, today announced the scheduled installation of its RefleXion® X1 platform with SCINTIX® biology-guided radiotherapy at Beverly Hills Cancer Center (BHCC), the first freestanding cancer center (FSCC) that has installed the RefleXion X1. “At BHCC, we are committed to advancing cancer care by integrating the latest innovations, ensuring our patients receive the highest quality, cutting-edge treatments,” said Arash...

RefleXion Showcases Pioneering Multi-Target Treatment (MTT) and Early Clinical Highlights at ASTRO

HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion® Medical, an external-beam theranostic oncology company, today announced it will showcase Multi-target Treatment (MTT), the groundbreaking upgrade for its RefleXion® X1 platform. This innovation allows physicians to combine SCINTIX® biology-guided radiotherapy with conventional stereotactic body radiotherapy (SBRT) in a single plan to treat patients with metastatic disease. The company will also highlight learnings from its early patient treatments. R...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.